Form 483

Bactolac Pharmaceutical, Inc. Form 483, 2021-11-19

FDA issued a Form 483 to Bactolac Pharmaceutical, Inc. on 2021-11-19 with 8 public-safe observations.

483· Form 483 issuedFoods & Cosmetics8 observations

Bactolac Pharmaceutical, Inc. · Hauppauge, United States · Issued November 19, 2021

Overview

  • 8 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

19 Nov 2021
21 CFR 111.315(a)

Criteria for establishing specifications

Cited by Meredith P Soehl

19 Nov 2021
21 CFR 111.315(a)

Criteria for establishing specifications

Cited by Meredith P Soehl

19 Nov 2021
21 CFR 111.70(e)

Specifications - contamination limits

Cited by Meredith P Soehl

19 Nov 2021
21 CFR 111.70(e)

Specifications - contamination limits

Cited by Meredith P Soehl

19 Nov 2021
21 CFR 111.75(c)

Specifications met - verify; finished batch

Cited by Meredith P Soehl

Inspected site

BPBactolac Pharmaceutical, Inc.Hauppauge, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 111.315(a)Cited across public-safe Form 483 observations2x
21 CFR 111.70(e)Cited across public-safe Form 483 observations2x
21 CFR 111.75(c)Cited across public-safe Form 483 observations2x
21 CFR 111.77(a)Cited across public-safe Form 483 observations2x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 8 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere